Luciana Borio Joins Insulet Corp. Board

Insulet Corporation has welcomed a new member to its Board of Directors.

Luciana Borio, M.D., has joined the governing body. A practicing physician at Johns Hopkins Hospital, Borio has a solid background in advancing major regulatory and policy agendas for the U.S. government. She worked for the U.S. Food and Drug Administration (FDA), serving as acting chief scientist and assistant commissioner for Counterterrorism Policy. Borio helped develop and execute the FDA’s medical countermeasures and public health responses to the 2009 H1N1 flu pandemic, the 2014 Ebola epidemic, and the 2015 Zika outbreak. She also served on the World Health Organization’s Emergency Preparedness and Response Scientific Advisory Group.  

“We are so pleased to welcome Dr. Borio to Insulet’s Board,” said Timothy Scannell, Insulet board chairman. “Dr. Borio’s unique experience of working with government agencies on some of the world’s most complex public health challenges, along with her clinical and scientific expertise, and her passion for advancing public health, will be incredibly valuable to our Board as we continue to advance our growth strategy.”

Borio also served on the National Security Council and the Council on Foreign Relations. She specializes in biodefense and medical countermeasures, emerging infectious diseases, medical product development, and public health emergencies. Most recently, she served as a member of the President’s Transition COVID-19 Advisory Board.
 
Last July, Borio joined ARCH Venture Partners, where she advises on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs. Prior to joining ARCH, she was senior vice president at In-Q-Tel, an independent, non-profit, strategic investment firm, and director for Medical and Biodefense Preparedness Policy at the National Security Council.
 
Borio earned a bachelor of sciene degree in zoology from George Washington University and a medical degree from George Washington University School of Medicine.
 
Insulet also announced that board member Sally W. Crawford retired after 13 years of service. “We thank Sally for her dedication, leadership, and guidance while serving on Insulet’s board,” said Scannell. “Sally has been a passionate advisor and a true friend to all of us. We are grateful for her immense contributions to Insulet and our mission to improve the lives of people with diabetes.”
 
Headquartered in Massachusetts, Insulet is dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.